Insulin glargine biosimilar (Merck Sharp & Dohme)

甘精胰岛素生物类似药（默沙东）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin glargine biosimilar (Merck Sharp & Dohme)
Drug Alias NameInsulina glargina (Merck Sharp & Dohme)甘精胰岛素生物仿制药（默沙东）Insulinum glarginum (Merck Sharp & Dohme)Insuline glargine (Merck Sharp & Dohme)LUSDUNA Nexvue +[8] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/01/03
Country/TerritoryEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme BvMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus

Other Information

ATC CodeA10AE04
Related LinksN/A